IMUGENE

ASX Announcement

Imugene Reports Further Complete Response and Partial Response in azer-cel Phase 1b Trial

- New Complete Response (CR) in CAR T Naïve Cohort (Cohort 2), in patient with marginal zone lymphoma (MZL) at their Day 28 assessment
- One further response in BTKi Combination Cohort (Cohort 3), with a patient with Richter's Transformation converting from stable disease (SD) to Partial Response (PR)
- The latest results add to the growing body of clinical evidence supporting azer-cel across multiple B-cell malignancies and different treatment settings
- Patient enrolment continues across ten US and five Australian sites

SYDNEY, Australia, 19 October 2026: Imugene Limited (ASX: IMU), a clinical-stage cellular therapy company, today reports two further responses in its ongoing Phase 1b basket study of azer-cel (azercabtagene zapreleucel), including one CR in the CAR T-naïve Cohort 2 and one PR in the Bruton Tyrosine Kinase inhibitor (BTKi) combination Cohort 3.

In Cohort 2, a patient with marginal zone lymphoma (MZL) achieved CR at their day 28 assessment. Cohort 2 has demonstrated an Overall Response Rate (ORR) of 81%, with 22 of 27 patients achieving a response.

In Cohort 3, a patient with Richter's Transformation who had previously demonstrated SD has now converted to a PR. Cohort 3 evaluates azer-cel in combination with a BTKi in patients whose disease has progressed on prior BTKi therapy.

Cohort 3 has now demonstrated an ORR of 86%, with six of seven patients achieving a response. All patients enrolled in this combination cohort have previously received and progressed on BTKi therapy, representing a heavily pre-treated population with high unmet medical need and fewer remaining treatment options.

For personal use only

These latest results add to the growing body of clinical evidence supporting azer-cel across diverse B-cell malignancies and patient populations with significant unmet medical need.



Further clinical updates will be reported as patient enrolment continues and data matures.

About the Phase 1b azer-cel trial

The ongoing, open-label Phase 1b trial of azer-cel in the U.S. and Australia evaluates three main patient populations: CAR T-relapsed patients, CAR T-naïve patients, and BTKi combination cohort of patients with B-cell malignancies who previously progressed on BTKi therapy. Across a broad range of non-Hodgkin lymphomas (including FL, CLL/SLL, MZL, WM, and MCL), treatment with azer-cel, lymphodepletion, and IL-2 has yielded meaningful clinical activity including multiple complete responses in the BTKi cohort, with a manageable safety and tolerability profile.

For more information please contact:

General Investor Enquiries
shareholderenquiries@imugene.com

Connect with us on LinkedIn @Imugene Limited
Watch us on YouTube @ImugeneLimited

For personal use only

About Imugene (ASX:IMU)

Imugene is a clinical stage cell therapy company developing an allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Imugene is focused on developing azer-cel for patients with B-cell cancers whose disease has progressed on existing treatments, including CAR T and BTK inhibitors.

Release authorised by the Executive Chairman, Imugene Limited.

For personal use only